- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Shaji Kumar, MD | Authors
Articles
Where Does Inhibition of BCL-2 Family Proteins Fit into the Multiple Myeloma Treatment Landscape?
May 05, 2022
Video
Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. Drs. Shaji Kumar and Jonathan Kaufman discuss how BCL-2 inhibitors fit into the different treatment options for multiple myeloma.
Other Investigational Agents Targeting BCL-2 Family Proteins for Multiple Myeloma Treatment
May 05, 2022
Video
Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. An explanation of the focus on BCL-2 inhibitors versus the development of MCL-1 inhibitors for multiple myeloma treatment.
Other Venetoclax-based Combination Regimens Being Evaluated in Multiple Myeloma
May 02, 2022
Video
Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. Jonathan Kaufman, MD, describes clinical trials looking at venetoclax resistance, including the CANOVA study.
Venetoclax in Combination with Carfilzomib for Multiple Myeloma Treatment
May 02, 2022
Video
Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. Oncologists discuss the use of carfilzomib for multiple myeloma and their typical treatment regimens of choice.
Venetoclax for Multiple Myeloma: The Phase 3 BELLINI Trial
April 18, 2022
Video
Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. Dr. Shaji Kumar reviews data from his BELLINI clinical trial studying venetoclax paired with bortezomib and dexamethasone for multiple myeloma treatment.
Venetoclax plus Dexamethasone for Multiple Myeloma Treatment
April 16, 2022
Video
Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. Dr. Jonathan Kaufman explains clinical trial data on the efficacy of dexamethasone with venetoclax for multiple myeloma treatment.